Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Wu-Mei-Wan is a classic traditional Chinese medicine (TCM) formula originally described in the *Shanghan Lun* (Treatise on Febrile Diseases). It is composed of ten herbal ingredients, including *Prunus mume* (Wu Mei), *Coptis chinensis* (Huang Lian), and *Aconitum carmichaelii* (Fu Zi). Traditionally used to treat "Jue Yin" stage disorders characterized by a complex of "upper heat and lower cold" (such as chronic diarrhea or parasitic infections), it is being investigated for its potential in treating primary (essential) hypertension, particularly in patients exhibiting this specific TCM syndrome. The formula is thought to regulate the autonomic nervous system and improve vascular resistance through the synergistic action of its multiple botanical constituents. Clinical research, such as trials conducted by the Affiliated Hospital of Shandong University of TCM, evaluates its efficacy as a dispensing granule formulation compared to standard therapies like valsartan.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on wu-mei-wan.